Executive leadership at LIXTE BIOTECHNOLOGY HOLDINGS.
Board of directors at LIXTE BIOTECHNOLOGY HOLDINGS.
Research analysts covering LIXTE BIOTECHNOLOGY HOLDINGS.
Recent press releases and 8-K filings for LIXT.
Lixte Biotechnology Holdings, Inc. Completes Share Exchange with Orbit Capital Inc.
LIXT
M&A
Convertible Preferred Issuance
- On December 30, 2025, Lixte Biotechnology Holdings, Inc. (PubCo) entered into a Share Exchange Agreement with Orbit Capital Inc. (Shareholder) ,.
- Under the agreement, Orbit Capital Inc. exchanged 2,700 shares of Lixte's Series C Preferred Stock ,.
- In return, Lixte issued 700,000 shares of its common stock and transferred 200 ordinary shares of its wholly-owned subsidiary, Liora Technologies Europe Ltd., to Orbit Capital Inc. ,.
- Following the exchange, all of Lixte's Series C Shares were cancelled, and Lixte now holds 800 ordinary shares of Liora. The transaction is intended to qualify as a tax-free reorganization ,.
Dec 31, 2025, 9:00 PM
LIXTE expands ovarian clear cell cancer trial and collaboration
LIXT
New Projects/Investments
- LIXTE Biotechnology Holdings, Inc. is expanding its clinical trial for ovarian clear cell cancer, doubling the patient enrollment from 21 to 42.
- The trial, combining LIXTE's proprietary compound LB-100 with GSK's Dostarlimab, now includes a second site at Northwestern University.
- LIXTE anticipates presenting initial findings from the trial's first 21 patients in the first half of 2026.
- LIXTE has committed to paying The University of Texas MD Anderson Cancer Center up to $1.5 million in milestone payments and a 3.75% royalty on annual net profit upon FDA approval for LB-100 in clear cell ovarian cancer.
Dec 23, 2025, 9:00 PM
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering
LIXT
- Lixte Biotechnology Holdings, Inc. announced a registered direct offering to raise approximately $4.3 million in gross proceeds.
- The offering includes the sale of 1,051,342 Common Units (or Pre-Funded Units) at a price of $4.09 per Common Unit.
- Each Common Unit consists of one share of Common Stock (or one Pre-Funded Warrant) and one Common Warrant, with the Common Warrants having an initial exercise price of $3.96 per share.
- The company expects to use the net proceeds from the offering for general corporate purposes and working capital.
- The transaction is anticipated to close on or about December 19, 2025.
Dec 22, 2025, 10:29 PM
Lixte Biotechnology Holdings Announces Registered Direct Offering
LIXT
- Lixte Biotechnology Holdings, Inc. has entered into definitive agreements for a registered direct offering with accredited investors.
- The offering involves the sale of 1,051,342 Common Units (or Pre-Funded Units), each priced at $4.09.
- The transaction is expected to generate approximately $4.3 million in aggregate gross proceeds.
- The company intends to use the net proceeds, combined with existing cash, for general corporate purposes and working capital.
Dec 18, 2025, 2:00 PM
LIXTE Biotechnology Acquires Liora Technologies' Proton Therapy Platform
LIXT
M&A
Convertible Preferred Issuance
New Projects/Investments
- LIXTE Biotechnology Holdings, Inc. completed the acquisition of Liora Technologies Europe Ltd. on November 24, 2025, marking its entry into the radiotherapy segment of cancer care.
- Liora Technologies specializes in electronically controlled proton therapy systems for cancer treatment, including its flagship LiGHT System.
- The consideration for the acquisition included 2,700 shares of Series C Preferred Stock (convertible into 2,700,000 common shares), 10.56 Bitcoin, 300 Ethereum, $440,000 in cash, and a royalty agreement for 10% of net revenues from the LiGHT equipment, capped at $45,000,000.
- LIXTE plans to develop a recurring revenue model through jointly operated treatment centers utilizing the LiGHT system.
Nov 25, 2025, 10:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more